<DOC>
	<DOC>NCT02835586</DOC>
	<brief_summary>It is a pilot study to evaluate the feasibility and the efficiency of local delivery of paclitaxel after stenting of long femoropopliteal arterial lesions TASC C and D before the realization of a large randomized multicentric study. Patients concerned are in critical ischemia.</brief_summary>
	<brief_title>STREAMER : STent Restenosis And MEdicaments Release</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>patients with critical ischemia of a lower limb with ankle pressure &lt; 50 mmHg lesions TASC C and D of the superficial femoral or popliteal artery patient allergic to paclitaxel patient with a cancer, a neutropenia, with immunosuppressor medicament or chemotherapy patient with contraindication to take 2 antiaggregants platelets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>critical ischemia</keyword>
	<keyword>restenosis</keyword>
	<keyword>femoropopliteal artery lesions TASC C and D</keyword>
</DOC>